Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14843883 | 0.84 | KMO (0.40) | KMOANPEPNPC1RAB9AHPGD | |
| SCHEMBL6018034 | 0.84 | CES2 (0.45) | LARS1ANPEPRNPEPDNPEPELANE | |
| SCHEMBL2800230 | 0.83 | SLC7A5 (0.46) | KMOPKMSLC7A5 | |
| SCHEMBL6897797 | 0.83 | NPC1 (0.38) | KMONPC1PKMRAB9APGR | |
| SCHEMBL5067796 | 0.81 | CA1 (0.38) | KMONPC1PKMRAB9ACA1 | |
| SCHEMBL4403267 | 0.81 | MDM2 (0.44) | KMONPC1RAB9A | |
| SCHEMBL29491550 | 0.79 | SLC7A5 (0.52) | LARS1ANPEPRNPEPDNPEPELANE | |
| SCHEMBL5067808 | 0.76 | HDAC8 (0.41) | NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL2333132 | 0.74 | KMT2A (0.57) | ADRA2AHTR2APOLB | |
| SCHEMBL7168442 | 0.74 | HSD11B1 (0.42) | KMONPC1RAB9AHPGDCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228540-A1 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | ENDOMET BIOSCIENCES, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11884749-B2 | Compositions and methods for treating endometriosis | ENDOMET BIOSCIENCES, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230121738-A1 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | ENDOMET BIOSCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| CN-113557030-A | Compositions and methods for treating endometriosis | 恩多梅特生物科学公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3883588-A1 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | Endomet Biosciences, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3280723-A1 | BACKBONE-CYCLIZED PEPTIDOMIMETICS | Polyphor AG (CH) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016162127-A1 | BACKBONE-CYCLIZED PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2016-10-13 | — | — | WO | disclosed |
| CN-103242431-A | Preparation method of bivalirudin | QILU PHARMACEUTICAL CO LTD | 2013-08-14 | — | — | CN | disclosed |
| US-20090325314-A1 | N-Methyl Scanning Mutagenesis | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-12-31 | — | — | US | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121738-A1 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | CTNNB1, CTNNBL1, WNT3A | GRN 1163/4885SORT1 2520/4885LARS1 2996/4885 |
| US-20240228540-A1 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | CTNNB1, CTNNBL1, WNT3A | GRN 1163/4885SORT1 2520/4885LARS1 2996/4885 |
| US-11884749-B2 | Compositions and methods for treating endometriosis | CTNNB1, CTNNBL1, WNT3A | GRN 1163/4885SORT1 2520/4885LARS1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.